European Journal of Cancer
Volume 42, Issue 1 , Pages 8-16 , January 2006

Adjuvant chemotherapy for non-small cell lung cancer: Ready for clinical practice?

  • M. Tiseo

      Affiliations

    • Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    • ,
  • V. Franciosi

      Affiliations

    • Oncologia Medica, Azienda Ospedaliera-Universitaria, Via Gramsci 14, 43100 Parma, Italy
    • ,
  • F. Grossi

      Affiliations

    • Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    • ,
  • A. Ardizzoni

      Affiliations

    • Oncologia Medica, Azienda Ospedaliera-Universitaria, Via Gramsci 14, 43100 Parma, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 0521702316; fax: +39 0521995448.

Received 9 August 2005 ,Accepted 9 August 2005.

References 

  1. Parkin DM. Global cancer statistics in the year of 2000. Lancet Oncol. 2001;2:533–543
  2. Jemal A, Murray T, Ward E, et al. Cancer statistics 2005. CA Cancer J Clin. 2005;55:10–30
  3. Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111:1710–1717
  4. Feld R, Rubinstein LV, Weisenberger TH. Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies. J Clin Oncol. 1984;2:1352–1358
  5. Pairolero PC, Williams DE, Bergstralh EJ, et al. Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg. 1984;38:331–338
  6. Thomas P, Rubinstein L. Cancer recurrence after resection: T1 N0 non-small cell lung cancer. Lung cancer study group. Ann Thorac Surg. 1990;49:242–247
  7. Martini N, Flehinger BJ, Zaman MB, et al. Prospective study of 445 lung carcinomas with mediastinal lymph node metastases. J Thorac Cardiovasc Surg. 1980;80:390–399
  8. PORT Meta-analysis Trialist Group . Post-operative radiotherapy in non-small cell lung cancer: systematic review and meta-analysis of individual patients data from nine randomized controlled trials. Lancet. 1998;352:257–263
  9. Anonymous . Effects of post-operative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung: the lung cancer study group. N Engl J Med. 1986;315:1377–1381
  10. Norton L, Simon R. Tumor size, sensitivity to therapy and the design of treatment protocols. Cancer Treat Rep. 1977;61:1307–1317
  11. Macdonald JS. Clinical overview: adjuvant therapy of gastrointestinal cancer. Cancer Chemother Pharmacol. 2004;54(Suppl. 1):4–11
  12. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350:379–392
  13. Pfister DG, Johnson DH, Azzoli CG, et al. American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004;22:330–353
  14. Wagner H, Bonomi P. Preoperative and post-operative therapy for non-small cell lung cancer. In:  Roth JA,  Ruckdeschel JC,  Weisenburger TH editor. Thoracic oncology. Philadelphia, PA: W.B. Saunders; 1995;p. 147–163
  15. George S, Schell MJ, Detterbeck FC, et al. Adjuvant chemotherapy for resected non-small cell carcinoma of the lung: why we still don’t know. Oncologist. 1998;3:35–44
  16. Non-Small Cell Lung Cancer Collaborative Group . Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ. 1995;311:899–909
  17. Keller SM, Adak S, Wagner H, et al. A randomized trial of post-operative adjuvant therapy in patients with completely resected stage II or IIIA non-small cell lung cancer. N Engl J Med. 2000;343:1217–1222
  18. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II or IIIA non-small cell lung cancer. J Natl Cancer Inst. 2003;95:1453–1461
  19. Crinò L, Clerici M, Figoli F, et al. Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Ann Oncol. 1995;6:347–353
  20. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351–360
  21. Waller D, Peake MD, Stephens RJ, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg. 2004;26:173–182
  22. Tada H, Tsuchiya R, Ichinose Y, et al. A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304). Lung Cancer. 2004;43:167–173
  23. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil–tegafur for adenocarcinoma of the lung. N Engl J Med. 2004;22:1713–1721
  24. Nakagawa M, Tanaka F, Tsubota N, et al. A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG) – the 4th study. Ann Oncol. 2005;16:75–80
  25. Hamada C, Ohta M, Wada H, et al. Survival benefit of oral UFT for adjuvant chemotherapy after completely resected non-small cell lung cancer. Proc Am Soc Clin Oncol. 2004;22:14S;[abstr. 7002]
  26. Langer CJ. The role of tegafur/uracil in pulmonary malignancy. Drugs. 1999;58(Suppl. 3):71–75
  27. Winton TL, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small cell lung cancer. N Engl J Med. 2005;352:2589–2597
  28. Shepherd F, Winton T, Livingston R, et al. The impact of adjuvant vinorelbine (VIN) and cisplatin (CIS) on quality of life (QoL): Results from The National Cancer Institute of Canada Clinical Trials Group Trial BR.10 randomized trial of VIN/CIS versus observation in stage IB and II non-small cell. Ann Oncol. 2004;15(Suppl. 3):[abstr. 6270]
  29. Strauss GM, Herndon J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633. Proc Am Soc Clin Oncol. 2004;22:14S;[abstr. 7019]
  30. Douillard J, Rosell R, Delena M, et al. ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I–III) non-small cell lung cancer (NSCLC) patients (pts): final results after 70 months median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association. Proc Am Soc Clin Oncol. 2005;23:624S;[abstr. 7013]
  31. Hotta K, Matsuo K, Ueoka H, et al. Role of adjuvant chemotherapy in patients with resected non-small cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol. 2004;22:3860–3867
  32. Sedrakyan A, van Der Meulen J, O’Byrne K, et al. Post-operative chemotherapy for non-small cell lung cancer: a systematic review and meta-analysis. J Thorac Cardiovasc Surg. 2004;128:414–419
  33. Bria E, Gralla RJ, Raftopoulos H, et al. Does adjuvant chemotherapy improve survival in non-small cell lung cancer (NSCLC)? A pooled-analysis of 6494 patients in 12 studies, examining survival and magnitude of benefit. Proc Am Soc Clin Oncol. 2005;23:655S;[abstr. 7140]
  34. Early Breast Cancer Trialists’ Collaborative Group . Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet. 1992;339:71–85
  35. International Multicenter Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995, 343, 939–44.

PII: S0959-8049(05)00842-7

doi: 10.1016/j.ejca.2005.08.031

European Journal of Cancer
Volume 42, Issue 1 , Pages 8-16 , January 2006

Article Tools